NKT Thera Closes $8M VC Round to Develop Rxs Based on NK Cell IP from Boston Institutions
March 18, 2009
NKT Thera Closes $8M VC Round to Develop Rxs Based on NK Cell IP from Boston Institutions
NKT licensed the IP from Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital. As a result, each of the Harvard Med-affiliated institutes has been awarded an undisclosed equity stake in the company.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Genomics vs. Cancer
March 26, 2009 / Genome Technology - Moving Target: CNVs in Disease
April 29, 2009 / Genome Technology - Egyptian Biotech Group Seeks 'Omics Partners
April 24, 2009 / GenomeWeb Daily News - Tech Transfer Tidbits
April 22, 2009 / - Dana-Farber, in Entrepreneurial Push, Founds Computational Biology Center
April 17, 2009 / BioInform